MHRA issues botox safety warning after rare botulism cases reported

• The Medicines and Healthcare products Regulatory Agency (MHRA) is strengthening safety warnings for all botulinum toxin type A products following rare reports of botulism linked to their use.
• Botulinum toxin, widely used in medical and cosmetic treatments such as botox, can in very rare cases cause botulism if the toxin's effect spreads beyond the injection site, leading to a serious and potentially life-threatening condition.
• The MHRA has collaborated with manufacturers to update product information, including patient leaflets, to more clearly highlight the risk of iatrogenic botulism, which is botulism caused by medical treatment.
• Patients are advised to seek immediate medical attention if they experience symptoms such as difficulty swallowing, slurred speech, breathing difficulties, or muscle weakness after treatment, as these can occur within days or up to four weeks.
• The MHRA also warns against unlicensed and counterfeit botulinum toxin products, urging the public to only seek treatment from appropriately qualified practitioners and to report any suspected side effects through the Yellow Card scheme.